In a February 27, 2026 appearance on the Joe Rogan Experience podcast, Health and Human Services Secretary Robert F. Kennedy Jr. articulated intentions to pursue reclassification of approximately 14 peptides from FDA Category 2 status back to Category 1, a policy reversal that, if implemented, would restore legal compounding access to compounds prohibited since September 2023.

“My hope is that they’re going to get moved to a place where people have access from ethical suppliers,” Kennedy stated, characterizing the proposed action as addressing both regulatory overreach concerns and unintended safety consequences that emerged following the 2023 restrictions.

For researchers and practitioners working within peptide science, Kennedy’s statement represents potential restoration of compounds removed from legal channels through September 2023 FDA action that reclassified 19 peptides to Category 2, a designation prohibiting their use in compounding formulations.

Understanding FDA Categories

The FDA maintains classification systems governing which “bulk drug substances” compounding pharmacies may legally incorporate into patient-specific formulations. These category designations carry substantial practical implications for compound accessibility.

Category 1 Definition (per official FDA documentation)

“These substances may be eligible for inclusion on the 503B bulks list, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on any other list. FDA does not intend to take action against an outsourcing facility for compounding drugs using bulk drug substances identified in category 1 provided that the conditions described in the guidance document are met.”

Practically, Category 1 status permits licensed compounding facilities to utilize designated substances in creating customized preparations with appropriate practitioner prescriptions, subject to applicable state and professional oversight requirements.

Category 2 Classification

Category 2 designation identifies substances the FDA has determined present “potential significant safety risks,” effectively prohibiting their incorporation into compounded formulations and eliminating legal patient access through traditional pharmaceutical compounding channels.

The September 2023 action moved 19 peptides into Category 2, removing them from legal compounding availability virtually overnight without advance notice to affected stakeholders.

Examining the Basis for 2023 Restrictions

Kennedy’s podcast statement suggested the FDA classified these peptides to Category 2 based on efficacy questions rather than documented safety concerns, a distinction carrying significant legal implications.

FDA authority to place substances on Category 2 lists requires identifying specific “safety signals” constituting concrete evidence of harm potential. 

Acting on efficacy concerns absent demonstrable safety risks represents potential regulatory authority overreach according to multiple legal challenges filed following the 2023 reclassifications.

Notably, scientific literature contains substantial research examining these compounds. 

For BPC-157 specifically, a 2025 systematic review identified 544 research articles spanning 1993-2024 investigating mechanisms, safety parameters, and therapeutic applications. Preclinical toxicity assessments across multiple animal species demonstrated favorable safety profiles, raising questions regarding the “insufficient evidence” rationale cited for restrictions.

Litigants challenging the reclassifications argued the FDA failed to follow legally mandated procedures and lacked transparency regarding safety data underlying the Category 2 placements. 

These legal challenges continue as Kennedy’s policy intentions emerge.

Unintended Consequences of Unregulated Supply Channels

Perhaps the most compelling policy argument for reversing 2023 restrictions involves predictable yet concerning outcomes that materialized following the prohibition: proliferation of unregulated supply channels filling demand vacuums created by eliminating legal access.

“There was a huge demand for peptides, and so a black market came out” Kennedy stated. “With the gray market, you have no idea [what you’re getting], and a lot of this stuff we’ve looked at is just, you know, very, very substandard.”

Compounds Potentially Affected by Reclassification

While Kennedy did not enumerate all 14 peptides during his podcast appearance, industry analysis suggests probable candidates include compounds with established research bases and substantial utilization histories.

BPC-157 (Body Protective Compound-157)

A pentadecapeptide sequence derived from gastric protective proteins, BPC-157 has generated substantial research interest for documented wound healing and tissue regenerative properties across multiple experimental models. Extensive scientific investigation has examined its potential applications.

Joe Rogan himself has publicly discussed BPC-157 usage. “I had tendonitis in my elbow, I started using BPC-157 and it was gone in two weeks,” Rogan stated, contributing to mainstream awareness of this compound.

Thymosin Alpha-1

Demonstrating well-characterized immunomodulatory properties, Thymosin Alpha-1 has been investigated across various immune function applications. Its Category 2 classification particularly impacted practitioners working with immune system modulation protocols.

CJC-1295 and Ipamorelin

These growth hormone secretagogues had established roles in research and clinical protocols targeting body composition, recovery optimization, and age-related hormonal decline. Research on CJC-1295 and Ipamorelin documents their pharmacological profiles.

GHK-Cu (Copper Peptide)

With extensive research supporting dermal applications including collagen synthesis and skin regeneration, GHK-Cu’s restriction surprised many given its relatively extended use history and favorable safety profile documented across multiple studies.

Timeline Considerations 

Kennedy’s podcast statement suggested formal FDA action could occur “within a couple of weeks” of February 27, though actual implementation timing depends on formal agency processes including bulk drug substance list updates and official guidance issuance to compounding facilities.

Several peptides have already initiated reclassification procedures. In September 2024, five peptides (CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank) were removed from Category 2 and referred to the Pharmacy Compounding Advisory Committee (PCAC) for evaluation, the procedural first step toward potential Category 1 designation.

However, maintaining realistic expectations proves prudent. 

As analysts have noted, Kennedy’s podcast comments do not constitute formal regulatory action. No FDA rule has changed. No Federal Register notice has been issued. No statute has been amended.

Formal implementation requires:

• Official FDA review and decision-making processes.
• Formal announcement through appropriate regulatory channels.
• Communication to state pharmacy boards and compounding facilities regarding implementation procedures.
• Establishment of any specific requirements or constraints governing compounding of designated substances.

Quality Assurance in Evolving Regulatory Landscapes

Assuming Category 1 reclassification proceeds, quality considerations become paramount. Quality standards demonstrate substantial variability, and peptide supply channels have historically attracted both exemplary and questionable operators.

Critical Quality Indicators:

1. Third-party analytical verification: Independent laboratory testing confirming identity (compound matches label claims) and purity (absence of contaminants, accurate concentration).
2. Manufacturing standards and documentation: Peptides produced in facilities maintaining rigorous quality systems, preferably in jurisdictions with strong regulatory oversight.
3. Transparent sourcing: Clear documentation regarding raw material origins, manufacturing facility quality standards.
4. Professional support infrastructure: Access to knowledgeable technical support capable of providing guidance on proper handling, storage requirements, and application protocols.
5. Appropriate storage and logistics: Careful handling all the way to delivery is essential for maintaining peptide stability and potency.

At DN Lab Research, our peptides adhere to all of these guidelines, ensuring the highest quality peptides available. Our peptides are:

✓ Third-party tested

✓ Manufactured in the USA

✓ Complete documentation is made available upon request

✓ Fast delivery 

✓ Support from our Peptide Therapy experts 

Research Perspectives and Scientific Context

Kennedy’s announcement occurs amid expanding mainstream peptide interest. 

The clinical success of GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) for weight management has introduced millions to peptide-based therapeutic concepts, generating curiosity regarding additional peptide applications.

Research applications span diverse areas:

• Metabolic regulation and body composition.
• Tissue repair and regenerative processes.
• Dermal applications and cellular senescence.
• Immune system modulation.
• Cognitive function and neuroprotection.
• Circadian rhythm optimization.
• Musculoskeletal health.

This expanding scientific interest combined with potential regulatory shifts favoring increased access positions peptide research at a transitional juncture, evolving from specialized research contexts toward broader scientific and clinical investigation.

Advance in Peptide Therapy with DN Lab Research

As regulatory frameworks evolve and compound access potentially expands, the importance of working with suppliers maintaining rigorous quality standards and providing proper technical support becomes increasingly critical.

DN Lab Research’s commitment extends beyond compound provision to encompass comprehensive support ensuring researchers can conduct investigations with confidence in material quality and consistency.

For those seeking expert guidance on peptide research protocols as regulatory landscapes evolve, our technical team remains available to provide support.

Book your 30-minute consultation with one of our peptide experts

Frequently Asked Questions

Do research peptides demonstrate favourable safety profiles?

Hundreds of peer-reviewed publications document a highly favourable safety profile for peptides. Peptides constitute naturally occurring biological molecules, amino acid sequences the body recognizes and utilizes for essential physiological functions. Quality sourcing and proper research protocols prove essential for ensuring appropriate safety standards in research contexts.

Has Kennedy’s announcement created immediate legal changes for peptide compounding?

No. Kennedy’s podcast statement articulates policy intentions and directional goals, not formal regulatory action. No FDA rule modifications have occurred, no official Federal Register notices have been issued, and compounding facilities have not received formal authorization to resume utilizing these peptides in formulations. Actual regulatory changes require formal FDA processes potentially requiring weeks to months for completion.

Which specific peptides will undergo Category 1 reclassification?

Kennedy did not enumerate all 14 peptides during his podcast appearance. Industry analysis suggests probable candidates include BPC-157, Thymosin Alpha-1, CJC-1295, Ipamorelin, and GHK-Cu based on historical utilization patterns and September 2024 advisory committee referrals. 

Written by Elizabeth Sogeke, BSc Genetics, MPH

Elizabeth is a science and medical writer with a background in Genetics and Public Health. She holds a BSc in Genetics and a Master’s in Public Health (MPH), with a focus on mitochondrial science, metabolic health, and healthy aging. Over the past several years, she has worked with leading peptide research laboratories and functional medicine clinics, creating trusted, clinically-informed content that bridges the latest developments in peptide and longevity research with real-world applications.